+1 858-523-8231
Login | Register
AA Blocks, Building Blocks, Catalysts, Inhibitors
Login | Register
Home Amines 56420-45-2
56420-45-2,MFCD00274554
Catalog No.:AA00I9ZQ

56420-45-2 | (8S,10S)-10-{[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione

Pack Size
Purity
Availability
Price(USD)
Quantity
  
5mg
>98.00%
3 weeks  
$502.00   $352.00
- +
10mg
>98.00%
3 weeks  
$618.00   $433.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA00I9ZQ
Chemical Name:
(8S,10S)-10-{[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione
CAS Number:
56420-45-2
Molecular Formula:
C27H29NO11
Molecular Weight:
543.5193
MDL Number:
MFCD00274554
SMILES:
OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](N)[C@H]([C@@H](O2)C)O)c2c(C1)c(O)c1c(c2O)C(=O)c2c(C1=O)cccc2OC
Properties
Properties
 
Form:
Solid  

Computed Properties
 
Complexity:
977  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
6  
Heavy Atom Count:
39  
Hydrogen Bond Acceptor Count:
12  
Hydrogen Bond Donor Count:
6  
Rotatable Bond Count:
5  
XLogP3:
1.3  

Downstream Synthesis Route
56420-45-2    81186-33-6   
C37H42N4O13 

[1]Locationinpatent:experimentalpartCoyne;Jones,Toni;Pharr,Todd[BioorganicandMedicinalChemistry,2011,vol.19,#1,p.67-76]

56420-45-2    252025-52-8   
C42H39Cl2N5O11 

[1]Patent:CN104356183,2017,B.Locationinpatent:Paragraph0089-0097

Literature

Title: Cersosimo RJ, et al. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol. 1986 Mar;4(3):425-39.

Title: Kashima H, et al. Epirubicin, Identified Using a Novel Luciferase Reporter Assay for Foxp3 Inhibitors, Inhibits Regulatory T Cell Activity. PLoS One. 2016 Jun 10;11(6):e0156643.

Title: Ozkan, A., et al. Epirubicin HCl toxicity in human-liver derived hepatoma G2 cells. Pol J Pharmacol, 2004. 56(4): p. 435-44.

Title: Bonadonna, G., et al. Drugs ten years later: epirubicin. Ann Oncol, 1993. 4(5): p. 359-69.

Title: Asanuma, F., et al. Antitumor activity of paclitaxel and epirubicin in human breast carcinoma, R-27. Folia Microbiol (Praha), 1998. 43(5): p. 473-4.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 56420-45-2
56390-09-1

56390-09-1

 25316-40-9

25316-40-9

 23541-50-6

23541-50-6

 56390-09-1

56390-09-1

 202350-68-3

202350-68-3

 72496-41-4

72496-41-4
Building Blocks
More >
Tags:56420-45-2 Molecular Formula|56420-45-2 MDL|56420-45-2 SMILES|56420-45-2 (8S,10S)-10-{[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione